Valuation: Viyash Scientific Limited

Market Cap 119B 1.24B 1.07B 997M 911M 1.72B 1.74B 11.79B 4.59B 59.78B 4.67B 4.57B 198B P/E 2027 *
39x
P/E 2028 * 23.5x
Enterprise Value 119B 1.24B 1.07B 997M 911M 1.72B 1.74B 11.79B 4.59B 59.78B 4.67B 4.57B 198B EV / Sales 2027 *
3.05x
EV / Sales 2028 * 2.66x
Free-Float
32.71%
Yield 2027 *
-
Yield 2028 * -
1 day+2.00%
1 week+10.18%
Current month+10.37%
1 month+10.84%
3 months+13.09%
6 months+26.74%
Current year+33.65%
1 week 253.9
Extreme 253.9
279.8
1 month 245.3
Extreme 245.3
281.15
Current year 178.4
Extreme 178.4
297.9
1 year 167.5
Extreme 167.5
297.9
3 years 86.03
Extreme 86.03
297.9
5 years 61.8
Extreme 61.8
297.9
10 years 42.45
Extreme 42.45
336.4
Manager TitleAgeSince
Chief Executive Officer 62 2025-12-15
Director of Finance/CFO - 2025-12-31
Chief Tech/Sci/R&D Officer - 2026-02-04
Director TitleAgeSince
Chairman 78 -
Director/Board Member 66 2020-08-24
Director/Board Member 57 2022-04-10
Change 5-day change 1-year change 3-year change Capi.($)
+2.00%+10.18%+58.56%+205.18% 1.24B
+0.75%+2.88%+81.35%+127.76% 1,111B
+0.29%+0.80%+53.18%+64.38% 658B
+0.62%+2.97%+28.46%+81.75% 467B
+0.92%+3.57%+43.82%+44.21% 369B
+1.25%+2.21%+26.77%+43.05% 301B
+3.02%+5.57%+4.99%+16.92% 256B
+0.41%+4.97%+54.76%+74.13% 240B
+2.86%+3.86%-16.20%-51.83% 207B
+0.59%+3.19%+29.66%+92.57% 182B
Average +1.29%+4.84%+36.53%+69.81% 379.23B
Weighted average by Cap. +0.98%+4.68%+47.32%+73.92%

Financials

2027 *2028 *
Net sales 38.99B 407M 349M 326M 298M 563M 569M 3.86B 1.5B 19.58B 1.53B 1.5B 64.78B 44.68B 467M 400M 374M 342M 645M 652M 4.43B 1.72B 22.44B 1.75B 1.71B 74.24B
Net income 3.44B 35.91M 30.77M 28.79M 26.32M 49.67M 50.2M 341M 132M 1.73B 135M 132M 5.71B 5.4B 56.35M 48.29M 45.17M 41.3M 77.94M 78.77M 535M 208M 2.71B 212M 207M 8.96B
Net Debt - -
Logo Viyash Scientific Limited
Viyash Scientific Limited, formerly SeQuent Scientific Limited, is an India-based integrated pharmaceutical company with a global footprint, operating in the domains of animal health (active pharmaceutical ingredients (APIs), and finished dosage formulations) and analytical services. The Company has eight manufacturing facilities, based in India, Turkey, Brazil, Spain and Germany. It is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It specializes in analytical and bioanalytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It offers analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer-developed methods or in-house method development.
Employees
2,900
Date Price Change Volume
26-08-25 278.20 +2.00% 560,813
26-08-24 ₹272.75 -1.27% 560,343
26-08-21 ₹276.25 +3.89% 322,934
26-08-20 ₹265.90 -2.22% 89,368
26-08-19 ₹271.95 +6.79% 780,161
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
278.20INR
Average target price
322.25INR
Spread / Average Target
+15.83%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VIYASH Stock